- Conditions
- Stroke
- Interventions
- Magnesium Chloride, Placebo
- Drug
- Lead sponsor
- Relox Medical, LLC
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Antidepressants Causing Adverse Effects in Therapeutic Use
- Interventions
- PGx test
- Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Opioid-use Disorder, Overdose of Opiate, Patient Participation
- Interventions
- Patient Reported Outcomes Electronic Survey
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Stimulant Use Disorder, People Living With HIV
- Interventions
- reSET, Standard of care
- Behavioral · Other
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Myocardial Infarction
- Interventions
- Recombinant human erythropoietin alfa (drug), Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hypogonadism
- Interventions
- Nasobol®, Androderm® (Positive Control)
- Drug
- Lead sponsor
- Acerus Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Burbank, California • Miami Gardens, Florida + 3 more
- Conditions
- Persistent Asthma
- Interventions
- German cockroach allergenic extract, Placebo for German cockroach allergenic extract
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Carcinoma, Transitional Cell
- Interventions
- Rogaratinib (BAY1163877), Chemotherapy
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 13 more
- Conditions
- Accidental Fall
- Interventions
- Gait and balance assessment, Medication review, Comorbidity review, Fall history, Assessment of feet/footwear, Assessment of visual acuity, Home safety risk assessment, Vitamin D Deficiency
- Behavioral
- Lead sponsor
- National Opinion Research Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cesarean Section, Anesthesia, Obstetric
- Interventions
- Intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg preservative-free morphine
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 15 Years to 55 Years · Female only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Childhood Absence Epilepsy, Juvenile Absence Epilepsy
- Interventions
- Brivaracetam Film-coated tablet, Brivaracetam oral solution
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 2 Years to 26 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Orange, California • Augusta, Georgia + 2 more
- Conditions
- Anxiety, Cardiovascular Disease
- Interventions
- Lexapro, Placebo, Supervised Aerobic Exercise
- Drug · Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Esophageal Diseases
- Interventions
- CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus, CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy
- Combination Product
- Lead sponsor
- Harvard Apparatus Regenerative Technology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
- Behavioral · Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Pain
- Interventions
- Intervention, Control
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Reagent Kits, Diagnostic
- Interventions
- Fingerprint sweat drug screen, Fingerprint sweat laboratory analysis
- Diagnostic Test
- Lead sponsor
- Intelligent Bio Solutions Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Decatur, Georgia • Berlin, New Jersey • Marlton, New Jersey
- Conditions
- Actinic Keratosis
- Interventions
- PEP005 (ingenol mebutate) Gel
- Drug
- Lead sponsor
- Peplin
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Paramus, New Jersey
- Conditions
- Smoking Behaviors
- Interventions
- Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.
- Drug
- Lead sponsor
- JT International SA
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee • San Antonio, Texas
- Conditions
- Cognitive Dysfunction, Dementia
- Interventions
- ToolboxDetect
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 35,403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
- Conditions
- Solid Tumors, KRAS Mutation
- Interventions
- BI 1823911, BI 1701963, Midazolam
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Dallas, Texas • Houston, Texas
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Interventions
- Bevacizumab, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
- Biological · Procedure · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS)
- Interventions
- Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
- Combination Product · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more